Actively Recruiting
Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Led by Chinese PLA General Hospital · Updated on 2024-01-12
50
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the relationship between the microbial community, the immune system, and the presence or absence of rapidly progressive interstitial lung disease (RPILD) in patients with anti-MDA5 antibody positive dermatomyositis. This observational study aims to better understand how changes in microecology may affect disease development in this specific patient population. Bronchoalveolar lavage samples from patients diagnosed with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease are collected and analyzed. The study focuses on examining the composition of the microbial community within these specimens to explore its connection to disease occurrence and progression. Participants will undergo bronchoalveolar lavage and provide samples for microbial analysis. Researchers will assess the relationship between the microbial community and interstitial lung disease presence over a 6-month period. The study includes clinical evaluations and monitoring of host immune responses to help understand disease mechanisms. The total participation duration corresponds to the 6-month outcome measurement timeframe.
CONDITIONS
Brief Title
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who meet the diagnostic criteria of dermatomyositis and are anti-MDA5 antibody positive
- Anti-MDA5 antibody positive dermatomyositis patients with rapidly progressive interstitial lung disease who meet the RPILD diagnostic criteria
- Must have undergone bronchoalveolar lavage
- Age 18 years or older
- Patients who have signed informed consent forms
You will not qualify if you...
- Patients with other connective tissue diseases
- Patients with interstitial lung disease or RPILD caused by infection, tumors, drugs, biochemistry, or other factors
- Pregnant or lactating patients
- Patients currently participating in any other clinical trial
- Patients who do not agree to be included in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to enrollment
Bronchoalveolar lavage specimens are collected from participants to analyze the relationship between microbial community and disease.
1 visit (in-person)
Duration - 6 months
Participants are observed to study the presence or absence of interstitial lung disease over time.
Periodic visits over 6 months
Trial Site Locations
Total: 1 location
1
PLA
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Z
Zhimei Duan, doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here